Table 2. Toxicity.

Event (cases/100py)*	Continuous	5 Days On/2 Days Off	p-value
Lactic Acidosis	11.4	0	0.04
Lipodystrophy	11.4	1.8	0.13
Peripheral neuropathy	13.7	9.2	0.72
Cholesterol/LFTs
Creatinine**
at week 72/73
Median (IQR) [N]
Total Cholesterol (mg/dL)	176 (141-194) [38]	192 (174-220) [43]	0.15
LDL Cholesterol (mg/dL)	96 (76-127) [36]	123 (106-139) [43]	0.08
HDL Cholesterol (mg/dL)	42 (35-50) [37]	45 (34-58) [43]	0.99
Triglycerides (mg/dL)	149 (88-212) [36]	144 (98-212) [42]	0.99
AST (IU/L)	21 (16-31) [27]	22 (17-24) [35]	0.99
ALT (IU/L)	20 (14-32) [27]	18 (13-25) [35]	0.99
Creatinine (mg/dL)	0.74 (0.62-0.83) [35]	0.76 (0.68-090) [43]	0.54

*stavudine patient years, subanalysis of participants receiving stavudine containing regimens.

**Cholesterol, liver function tests and creatinine for patients followed 72/73 weeks (all HAART regimens).